Roche Claims Success Against Breast Cancer In Phase III Clinical Trials

(MENAFN- Swissinfo) Swiss pharmaceutical giant Roche has achieved positive results from the phase III evERA study combining its experimental treatments giredestrant and everolimus against a specific form of breast cancer. This content was published on September 22, 2025 - 12:05 2 minutes Keystone-SDA

• Français fr Roche revendique un succès clinique contre le cancer du sein Original Read more: Roche revendique un succès clinique contre le cancer du sei

The combination of the two substances, administered orally, resulted in a“significant” increase in the survival time of patients without disease progression, compared with the current standard of treatment consisting of endocrine therapy and everolimus.

+Get the most important news from Switzerland in your inbox

In its press releaseExternal link on Monday, the Swiss multinational stated that it did not at this stage have mature data on the total survival rate of patients with locally advanced or metastatic oestrogen receptor-positive (ER+) and human epidermal growth factor receptor-negative breast cancer who had already undergone prior treatment.

The adverse side effects observed were comparable to those of the two substances administered separately.

More More Drug pricing How a clash with Roche exposed cracks in Switzerland's drug pricing system

This content was published on Sep 19, 2025 Switzerland's new process to speed up patient access to the latest drugs hit its first major hurdle in a clash with Roche.

Read more: How a clash with Roche exposed cracks in Switzerland's drug pricing syste

MENAFN22092025000210011054ID1110095249